Business Context and Reporting Period
Company: InfuSystem Holdings, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: InfuSystem is a provider of ambulatory infusion pump management services for oncologists in the United States. The company rents electronic ambulatory infusion pumps and supplies to over 1,300 oncology practices, primarily for colorectal cancer chemotherapy. It bills third-party payors and patients directly. The company operates as a single segment and is a smaller reporting company.
Key Financial Metrics (Year Ended Dec 31, 2009)
| Metric | 2009 (in thousands) | 2008 (in thousands) |
|---|---|---|
| Net Revenues | $38,964 | $35,415 |
| Cost of Revenues | $10,327 | $9,191 |
| Gross Profit | $28,637 | $26,224 |
| Operating Expenses | $23,309 | $21,438 |
| Operating Income | $5,328 | $4,786 |
| Net Income | $774 | $9,959 |
| Cash and Cash Equivalents | $7,750 | $11,513 |
| Total Assets | $114,690 | $116,220 |
| Total Debt (Long-term + Current) | $24,141 | $30,669 |
| Stockholders' Equity | $81,465 | $80,073 |
Key Ratios & Margins:
- Gross Margin: ~73.5% (2009) vs ~74.0% (2008)
- Operating Margin: ~13.7% (2009) vs ~13.5% (2008)
- Net Margin: ~2.0% (2009) vs ~28.1% (2008) - *Note: 2008 net income was significantly boosted by a $9.8M gain on derivatives.*
- Provision for Doubtful Accounts: $4.0M (10.3% of revenue) vs $3.2M (9.0% of revenue).
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 10% to $38.96M, driven by new customer facilities, improved billing efficiency, and increased reimbursement rates.
- Net Income Decline: Net income dropped significantly to $0.77M from $9.96M. This decrease is primarily due to the absence of a $9.815M unrealized gain on derivatives recorded in 2008. In 2009, the company recorded a $78k loss on derivatives.
- Debt Reduction: Total debt decreased by approximately $6.5M due to significant principal payments ($8.565M) on the term loan with Kimberly-Clark (formerly I-Flow).
- Cash Flow: Cash provided by operating activities decreased to $9.7M from $10.9M, largely due to an increase in accounts receivable timing. Cash used in investing activities increased to $4.6M due to capital expenditures for new pumps and software.
- Bad Debt Provision: The provision for doubtful accounts increased to 10% of revenue from 9%, reflecting a slight increase in billings directly to patients.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Strategy: Management plans to expand into treatments for head, neck, and gastric cancers and pursue strategic alliances or acquisitions (though acquisitions are currently restricted by debt covenants).
- Liquidity: Management believes current funds and operating cash flows are sufficient for the next 12 months. Capital expenditures for 2010 are expected to range between $4M and $5M.
- Economic Impact: Management does not believe the global financial crisis will have a material adverse impact on revenues or liquidity for the next 12 months.
Risks and Contingencies
- Medicare Dependency: The company is heavily dependent on its Medicare Supplier Number. Loss of this number would prevent billing Medicare and invalidate other third-party contracts. Medicare accounted for ~31% of gross billings.
- Reimbursement Rates: Changes in third-party reimbursement rates or healthcare policies could materially adversely affect revenues.
- Drug Availability: Shortages of chemotherapy drugs (e.g., 5-Fluorouracil) could negatively impact operations.
- Competition: The industry is competitive with regional providers, hospital-owned DME providers, and home care infusion providers.
- Warrant Overhang: The company has a significant number of outstanding warrants (35.1M) which may depress stock price and limit liquidity. A warrant exchange offer was announced in February 2010.
Unusual Items
- Derivative Volatility: The 2008 financial results were skewed by a $9.8M gain on derivatives (warrant liability fair value changes). 2009 results included a small loss on derivatives.
- CEO Separation: Former CEO Steve Watkins resigned in September 2009. The company recorded compensation and benefits related to his separation agreement.
Investor Verification Checklist
- Medicare Compliance: Verify the status of the company's Medicare Supplier Number and accreditation (CHAP) to ensure continued eligibility for the largest payor segment.
- Reimbursement Trends: Monitor changes in Medicare and commercial insurance reimbursement rates for ambulatory infusion pumps.
- Debt Covenants: Review the Credit and Guaranty Agreement with Kimberly-Clark to confirm compliance with fixed charge coverage and leverage ratios, noting restrictions on dividends and acquisitions.
- Warrant Exchange Offer: Assess the outcome of the February 2010 warrant exchange offer and its impact on the "warrant overhang" and potential dilution.
- Bad Debt Reserves: Analyze the trend in the provision for doubtful accounts (10% of revenue) and the aging of accounts receivable.
- Capital Expenditures: Verify the necessity and ROI of the planned $4M-$5M capital expenditure for new pumps and software in 2010.